Willow Biosciences Inc (WLLW) - Total Assets
Based on the latest financial reports, Willow Biosciences Inc (WLLW) holds total assets worth CA$2.31 Million CAD (≈ $1.67 Million USD) as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Willow Biosciences Inc net assets for net asset value and shareholders' equity analysis.
Willow Biosciences Inc - Total Assets Trend (2000–2024)
This chart illustrates how Willow Biosciences Inc's total assets have evolved over time, based on quarterly financial data.
Willow Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Willow Biosciences Inc's total assets of CA$2.31 Million consist of 26.4% current assets and 73.6% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 13.4% |
| Accounts Receivable | CA$39.00K | 1.6% |
| Inventory | CA$56.00K | 2.3% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2000–2024)
This chart illustrates how Willow Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see WLLW market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Willow Biosciences Inc's current assets represent 26.4% of total assets in 2024, a decrease from 100.0% in 2000.
- Cash Position: Cash and equivalents constituted 13.4% of total assets in 2024, up from 0.1% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is inventory at 2.3% of total assets.
Willow Biosciences Inc Competitors by Total Assets
Key competitors of Willow Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Willow Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.01 | 1.42 | 9.12 |
| Quick Ratio | 1.01 | 1.29 | 8.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$17.00K | CA$702.00K | CA$12.22 Million |
Willow Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Willow Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.89 |
| Latest Market Cap to Assets Ratio | 2.07 |
| Asset Growth Rate (YoY) | -62.7% |
| Total Assets | CA$2.49 Million |
| Market Capitalization | $5.15 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Willow Biosciences Inc's assets at a significant premium (2.07x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Willow Biosciences Inc's assets decreased by 62.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Willow Biosciences Inc (2000–2024)
The table below shows the annual total assets of Willow Biosciences Inc from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$2.49 Million ≈ $1.80 Million |
-62.70% |
| 2023-12-31 | CA$6.67 Million ≈ $4.83 Million |
-63.23% |
| 2022-12-31 | CA$18.15 Million ≈ $13.13 Million |
-48.17% |
| 2021-12-31 | CA$35.02 Million ≈ $25.33 Million |
+60.15% |
| 2020-12-31 | CA$21.86 Million ≈ $15.82 Million |
-35.47% |
| 2019-12-31 | CA$33.88 Million ≈ $24.51 Million |
+3403.87% |
| 2018-12-31 | CA$967.03K ≈ $699.54K |
+33.53% |
| 2017-12-31 | CA$724.18K ≈ $523.86K |
-57.39% |
| 2016-12-31 | CA$1.70 Million ≈ $1.23 Million |
-29.64% |
| 2015-12-31 | CA$2.42 Million ≈ $1.75 Million |
-0.55% |
| 2014-12-31 | CA$2.43 Million ≈ $1.76 Million |
+1.79% |
| 2013-12-31 | CA$2.39 Million ≈ $1.73 Million |
+11.65% |
| 2012-12-31 | CA$2.14 Million ≈ $1.55 Million |
-29.74% |
| 2011-12-31 | CA$3.04 Million ≈ $2.20 Million |
-18.37% |
| 2010-12-31 | CA$3.73 Million ≈ $2.70 Million |
-33.03% |
| 2009-12-31 | CA$5.56 Million ≈ $4.02 Million |
+27.20% |
| 2008-12-31 | CA$4.37 Million ≈ $3.16 Million |
+42.36% |
| 2007-12-31 | CA$3.07 Million ≈ $2.22 Million |
+394.02% |
| 2006-12-31 | CA$621.91K ≈ $449.88K |
+31.68% |
| 2005-12-31 | CA$472.29K ≈ $341.65K |
+44455.66% |
| 2004-12-31 | CA$1.06K ≈ $766.79 |
-98.90% |
| 2002-12-31 | CA$96.40K ≈ $69.74K |
-2.90% |
| 2001-12-31 | CA$99.28K ≈ $71.81K |
-9.61% |
| 2000-12-31 | CA$109.83K ≈ $79.45K |
-- |
About Willow Biosciences Inc
Willow Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. The company has licensing and development partnership with Laurus Labs to develop and commercialize active pharmaceutical ingredients and other ingredients. Willow Biosciences Inc. was founded in 20… Read more